DSIJ Mindshare

Markets may open lower amid global trade tensions and growth concerns

DSIJ Intelligence-3 0 641 Article rating: 5.0

Considering the early action in SGX Nifty and the Asian peers, it appears that the Indian benchmark indices are expected to open lower. Digging deeper, scaring the market participants the most is the global growth forecast from IMF as it cut global growth outlook amidst global trade tensions. Also, the US President Donald Trump threatened to impose tariffs on $11 billion worth of European Union (EU) products and the latest statement from the EU suggests these countries will retaliate. At the time of writing, SGX Nifty was trading around 11,709 levels down by 40 points.

Shilpa Medicare receives approval for Bortezomib for Injection

Advait Dharmadhikari 0 2894 Article rating: 4.0

Shilpa Medicare has received a tentative approval for its ANDA , Bortezomib for Injection, 3.5mg/vial from the USFDA. Bortezomib for Injection, 3.5mg/vial is a generic equivalent of reference listed drug (RLD), VELCADE used in the treatment of patients with multiple myeloma and Mantle Cell Lymphoma as recommended in the label approved by the FDA.According to IQVIA MAT Q4 2018 data, the US market for Bortezomib for Injection, 3.5mg/vial is approximately US$609 million.

RSS
First65706571657265736575657765786579Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR